BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $149,991.68 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of BridgeBio Pharma stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the completion of the transaction, the chief financial officer now directly owns 102,464 shares in the company, valued at $3,705,098.24. This represents a 3.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded up $0.80 during mid-day trading on Wednesday, reaching $36.29. 4,162,895 shares of the company traded hands, compared to its average volume of 2,811,407. The company’s fifty day moving average is $31.53 and its two-hundred day moving average is $27.79. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $37.81. The stock has a market cap of $6.86 billion, a PE ratio of -15.06 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BBIO shares. Scotiabank lifted their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Evercore ISI lifted their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Finally, Bank of America boosted their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average target price of $49.08.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of BridgeBio Pharma by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after buying an additional 879,059 shares during the last quarter. Janus Henderson Group PLC raised its holdings in BridgeBio Pharma by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock worth $134,672,000 after acquiring an additional 89,521 shares during the period. Farallon Capital Management LLC boosted its holdings in BridgeBio Pharma by 140.1% during the fourth quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock valued at $115,111,000 after acquiring an additional 2,448,000 shares during the period. Frazier Life Sciences Management L.P. grew its position in shares of BridgeBio Pharma by 1.1% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Capital Research Global Investors increased its stake in shares of BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock worth $96,774,000 after purchasing an additional 912,439 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.